The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 24, 2025

Filed:

Aug. 09, 2019
Applicant:

Texas Tech University System, Lubbock, TX (US);

Inventors:

Nadezhda German, Amarillo, TX (US);

Ruwein Zhang, Sugar Land, TX (US);

Wei Wang, Sugar Land, TX (US);

Constantinos Mikelis, Amarillo, TX (US);

Luca Cucullo, Amarillo, TX (US);

Assignee:

Texas Tech University System, Lubbock, TX (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07C 275/30 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07C 275/30 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01);
Abstract

Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs.


Find Patent Forward Citations

Loading…